Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
February 23, 2018
AbbVie

AbbVie Increases Dividend and Announces New Stock Repurchase Program

AbbVie Increases Dividend and Announces New Stock Repurchase Program

-
AbbVie
-
February 23, 2018

NORTH CHICAGO, Ill., Feb. 15, 2018 /PRNewswire/ -- The board of directors of AbbVie (NYSE: ABBV) increased the company's quarterly cash dividend by 35 percent from $0.71per share to $0.96 per share and authorized a new $10 billion stock repurchase program. 

The cash dividend is payable May 15, 2018 to stockholders of record at the close of business on April 13, 2018.

Since the company's inception in 2013, AbbVie has increased its dividend by 140 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

The stock repurchase program supersedes any existing repurchase authorizations. Purchases may be made from time to time in management's discretion. The stock repurchase authorization permits shares to be repurchased in open market or private transactions, has no time limit and may be discontinued at any time.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.  In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

 

SOURCE AbbVie

Contact(s)

Media

Adelle Infante
(847) 938-8745

or Investors

Liz Shea
(847) 935-2211

Last updated:
February 23, 2018

AbbVie

We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

NORTH CHICAGO, Ill., Feb. 15, 2018 /PRNewswire/ -- The board of directors of AbbVie (NYSE: ABBV) increased the company's quarterly cash dividend by 35 percent from $0.71per share to $0.96 per share and authorized a new $10 billion stock repurchase program. 

The cash dividend is payable May 15, 2018 to stockholders of record at the close of business on April 13, 2018.

Since the company's inception in 2013, AbbVie has increased its dividend by 140 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

The stock repurchase program supersedes any existing repurchase authorizations. Purchases may be made from time to time in management's discretion. The stock repurchase authorization permits shares to be repurchased in open market or private transactions, has no time limit and may be discontinued at any time.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.  In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

 

SOURCE AbbVie

Contact(s)

Media

Adelle Infante
(847) 938-8745

or Investors

Liz Shea
(847) 935-2211

Last updated:
February 23, 2018

AbbVie

We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail